Substudy 02D: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Melanoma Brain Metastasis (MK-3475-02D/KEYMAKER-U02)
Clinical trial NCT04700072 · COMPLETED
Trial details
- NCT number
- NCT04700072
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-05-03
- Primary completion
- 2025-10-17
- Enrollment
- 56
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.